thereof, as defined above, for the preparation of a medicinal product for the treatment of infertility in a non-diabetic female mammal or for favoring fertility in a non-diabetic female mammal.

A fourth aspect of the invention relates to a method for the treatment of infertility or for favoring normal reproduction and fertility in a non-diabetic female mammal, which comprises administering a therapeutically effective amount of a tungsten (VI) salt or a solvate thereof, as defined above.

A fifth aspect of the invention relates to a tungsten (VI) salt or a solvate thereof, when used for favoring normal reproduction and fertility in a non-diabetic female mammal, or when used for improving the efficacy of an assisted reproductive technique in a mammal.

A sixth aspect of the invention relates to a composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, when used for favoring normal reproduction and fertility in a non-diabetic female mammal, or when used for improving the efficacy of an assisted reproductive technique applied to a mammal.

A seventh aspect of the invention relates to a food composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, when used for favoring normal reproduction and fertility in a non-diabetic female mammal.

DETAILED DISCLOSURE OF THE INVENTION

As indicated above, according to a first aspect the present invention relates to a tungsten (VI) salt or a solvate thereof, for the treatment of infertility in a non-diabetic female mammal or for favoring and/or contributing to normal reproduction and fertility in a non-diabetic female mammal.

The term “favoring normal reproduction and fertility” or “contributing to normal

reproduction and fertility" refers to contributing to normal reproduction and fertility or improving normal reproduction and fertility (reducing the times for achieving pregnancy), "normal reproduction and fertility" being understood as a state of fertility in which pregnancy is achieved following the definitions provided above:

* in a subfertility situation: pregnancy is achieved in a period of 12 months of regular, unprotected sexual intercourse; and

* in an infertility situation: pregnancy is achieved after a period 12 months of regular, unprotected sexual intercourse. The need to restore and/or promote ovulation, improve oocyte and embryo quality, increase zygote implantation on the uterine wall, regulate hypothalamic-pituitary-ovarian axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia are included herein.

In the context of the present invention, the term "assisted reproductive technique" encompasses any assisted reproductive technique or artificial insemination, being

CLAIMS

1. A tungsten (VI) salt or a solvate thereof, when used for favoring normal reproduction and fertility in a non-diabetic female mammal, or when used for improving the efficacy of an assisted reproductive technique in a mammal.

2. The tungsten (VI) salt according to Claim 1, wherein the mammal is a human.

3. The tungsten (VI) salt according to Claim 1 or Claim 2, wherein said salt is administered in a daily dose of between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the mammal.

4. The tungsten (VI) salt according to any one of Claims 1 to 3, wherein said salt comprises a tungsten (VI) anion and a pharmaceutically, veterinary or dietetically acceptable cation.

5. The tungsten (VI) salt according to any one of Claims 1 to 4, wherein the cation is an alkaline or alkaline earth cation.

6. The tungsten (VI) salt according to any one of Claims 1 to 5, wherein the cation is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc.

7. The tungsten (VI) salt according to Claim 6, wherein the cation is sodium.

8. The tungsten (VI) salt according to Claim 6, wherein the cation is zinc.

9. The tungsten (VI) salt according to any one of Claims 1 to 8, wherein the tungsten (VI) anion is selected from WO_4^{2-}, HWO_4^-, $W_2O_7^{2-}$ and $HW_2O_7^-$ ions.

10. The tungsten (VI) salt according to Claim 9, wherein the anion is WO_4^{2-}.

11. The tungsten (VI) salt according to any one of Claims 1 to 10, wherein the solvate is dihydrate.

12. A composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, when used for favoring normal reproduction and fertility in a non-diabetic female mammal, or when used for improving the efficacy of an assisted reproductive technique applied to a mammal.

13. The composition according to Claim 12, wherein the excipient or vehicle is

pharmaceutically or veterinary acceptable, and the composition is a pharmaceutical composition when used for increasing the efficacy of an assisted reproductive technique applied to a mammal.

14. The composition according to Claim 12 or Claim 13, wherein the composition is in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablets, solution, suspension, syrup or granules.

15. A food composition comprising a tungsten (VI) salt or a solvate thereof, at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, when used for favoring normal reproduction and fertility in a non-diabetic female mammal.

16. The composition according to Claim 15, wherein the food composition is a liquid composition or a beverage.

17. The composition according to Claim 15, wherein the food composition is a solid composition.

18. The food composition according to Claim 15 or Claim 16, wherein the food composition is a nutritional supplement or complement.

19. The composition according to Claim 13 or 14, wherein the composition comprises sucrose.

20. The food composition according to any one of Claims 15 to 18, wherein the food composition comprises sucrose.